Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 38 results
Filters: First Letter Of Last Name is K  [Clear All Filters]
Found 38 results.
Skip Alphabet Links A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

K

Kalayjian RC, Machekano RN, Rizk N, et al. "Pretreatment levels of soluble cellular receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral therapy." J. Infect. Dis.. 2010;201(12):1796-805.
Kalayjian RC, Spritzler J, Matining RM, et al. "Older HIV-infected patients on antiretroviral therapy have B-cell expansion and attenuated CD4 cell increases with immune activation reduction." AIDS. 2013;27(10):1563-71.
Kalayjian RC, Wu K, Evans S, et al. "Proteinuria is associated with neurocognitive impairment in antiretroviral therapy treated HIV-infected individuals." J. Acquir. Immune Defic. Syndr.. 2014;67(1):30-5.
Kalayjian RC, Franceschini N, Gupta SK, et al. "Suppression of HIV-1 replication by antiretroviral therapy improves renal function in persons with low CD4 cell counts and chronic kidney disease." AIDS. 2008;22(4):481-7.
Kallianpur AR, Hulgan T, Canter JA, et al. "Hemochromatosis (HFE) gene mutations and peripheral neuropathy during antiretroviral therapy." AIDS. 2006;20(11):1503-13.
Kang M, Hollabaugh K, Pham V, et al. "Virologic and serologic outcomes of mono versus dual HBV therapy and characterization of HIV/HBV coinfection in a US cohort." J. Acquir. Immune Defic. Syndr.. 2014;66(2):172-80.
Kang M, Chung RT. "The role of early viral decline in the treatment of hepatitis C in HIV-1-coinfected persons." J. Acquir. Immune Defic. Syndr.. 2007;46(3):371-3.
Kang M, Cu-Uvin S. "Association of HIV viral load and CD4 cell count with human papillomavirus detection and clearance in HIV-infected women initiating highly active antiretroviral therapy." HIV Med.. 2012;13(6):372-8.
Kantor R, Smeaton L, Vardhanabhuti S, et al. "Pretreatment HIV Drug Resistance and HIV-1 Subtype C Are Independently Associated With Virologic Failure: Results From the Multinational PEARLS (ACTG A5175) Clinical Trial." Clin. Infect. Dis.. 2015;60(10):1541-9.
Kantor R, Bettendorf D, Bosch RJ, et al. "HIV-1 RNA levels and antiretroviral drug resistance in blood and non-blood compartments from HIV-1-infected men and women enrolled in AIDS clinical trials group study A5077." PLoS ONE. 2014;9(4):e93537.
Kassaye SG, Grossman Z, Balamane M, et al. "Transmitted HIV Drug Resistance Is High and Longstanding in Metropolitan Washington, DC." Clin. Infect. Dis.. 2016.
Katsounas A, Frank AC, Lempicki RA, Polis MA, Asmuth DM, Kottilil S. "Differential Specificity of Interferon-alpha Inducible Gene Expression in Association with Human Immunodeficiency Virus and Hepatitis C Virus Levels and Declines in vivo." J AIDS Clin Res. 2015;6(1).
Keane NM, Roberts SG, Almeida C-AM, et al. "High-avidity, high-IFNγ-producing CD8 T-cell responses following immune selection during HIV-1 infection." Immunol. Cell Biol.. 2012;90(2):224-34.
Kearney MF, Wiegand A, Shao W, et al. "Origin of Rebound Plasma HIV Includes Cells with Identical Proviruses That Are Transcriptionally Active before Stopping of Antiretroviral Therapy." J. Virol.. 2016;90(3):1369-76.
Keil K, Hochreitter J, DiFrancesco R, et al. "Integration of atazanavir into an existing liquid chromatography UV method for protease inhibitors: validation and application." Ther Drug Monit. 2007;29(1):103-9.
Kelesidis T, Yang OO, Kendall MA, Hodis HN, Currier JS. "Dysfunctional HDL and progression of atherosclerosis in HIV-1-infected and -uninfected adults." Lipids Health Dis. 2013;12:23.
Kelesidis T, Jackson N, McComsey GA, et al. "Oxidized lipoproteins are associated with markers of inflammation and immune activation in HIV-1 infection." AIDS. 2016;30(17):2625-2633.
Kelesidis T, Kendall MA, Yang OO, Hodis HN, Currier JS. "Biomarkers of microbial translocation and macrophage activation: association with progression of subclinical atherosclerosis in HIV-1 infection." J. Infect. Dis.. 2012;206(10):1558-67.
Kelesidis T, Tran TTien T, Brown TT, et al. "Changes in plasma levels of oxidized lipoproteins and lipoprotein subfractions with atazanavir-, raltegravir-, darunavir-based initial antiviral therapy and associations with common carotid artery intima-media thickness: ACTG 5260s." Antivir. Ther. (Lond.). 2016.
Kelesidis T, Tran TTien T, Stein JH, et al. "Changes in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s." Clin. Infect. Dis.. 2015;61(4):651-60.
Kelesidis T, Moser C, Stein JH, et al. "Changes in Markers of T-Cell Senescence and Exhaustion With Atazanavir-, Raltegravir-, and Darunavir-Based Initial Antiviral Therapy: ACTG 5260s." J. Infect. Dis.. 2016.
Kelesidis T, Kendall MA, Yang OO, Hodis H, Currier JS. "Perturbations of circulating levels of RANKL-osteoprotegerin axis in relation to lipids and progression of atherosclerosis in HIV-infected and -uninfected adults: ACTG NWCS 332/A5078 Study." AIDS Res. Hum. Retroviruses. 2013;29(6):938-48.
Kemmer N, Hua L, Andersen JW, Chung RT, Butt AA, Sherman KE. "Health-related quality of life in subjects with HCV/HIV coinfection: results from ACTG 5178 study." J. Viral Hepat.. 2012;19(11):792-800.
Kendall MA, Andersen JW, van der Horst C. "A reduced frequency visit schedule underreports adverse events that resulted in dose modifications or treatment discontinuations in HIV/AIDS clinical trials: ACTG DACS 207." Contemp Clin Trials. 2006;27(3):287-94.
Kendall MA, Tassiopoulos K, McComsey GA, Yin MT. "Fractures Are Not Associated with CD8(+) T Cell Activation: An Analysis of the ACTG ALLRT Study." AIDS Res. Hum. Retroviruses. 2015;31(8):769-71.
J Kilby M, R Bucy P, Mildvan D, et al. "A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024)." J. Infect. Dis.. 2006;194(12):1672-6.
Kiser JJ, Lu D, Rosenkranz SL, et al. "Boceprevir and Antiretroviral Pharmacokinetic Interactions in HIV/HCV Co-infected Persons: AIDS Clinical Trials Group Study A5309s." Drugs R D. 2017;17(4):557-567.
Kitahata MM, Gange SJ, Abraham AG, et al. "Effect of early versus deferred antiretroviral therapy for HIV on survival." N. Engl. J. Med.. 2009;360(18):1815-26.
Koelsch KK, Liu L, Haubrich R, et al. "Dynamics of total, linear nonintegrated, and integrated HIV-1 DNA in vivo and in vitro." J. Infect. Dis.. 2008;197(3):411-9.
Kojic EMilunka, Kang M, Cespedes MS, et al. "Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1-infected women." Clin. Infect. Dis.. 2014;59(1):127-35.

Pages